keyword
https://read.qxmd.com/read/38190194/novel-bioequivalent-oral-disintegrating-tablet-of-aripiprazole-prepared-by-direct-compression-technique-with-shortened-disintegration-time
#1
JOURNAL ARTICLE
Do Hwan Kim, Jun Soo Park, Min Young Jeong, In Gyu Yang, Wookyung Kim, Seung Bo Shim, Hye Seon Kim, Hyun Yang Park, Myoung Jin Ho, Myung Joo Kang
Herein, we aimed to formulate a novel oral disintegrating tablet (ODT) of aripiprazole (ARP) capable of rapid disintegration using a direct compression technique. Different ODTs were fabricated with directly compressible excipients, and their disintegration time, wettability (water absorption ratio and wetting time), and mechanical properties (hardness and friability) were evaluated. The optimized ODT comprised F-Melt® type C, Prosolv® SMCC HD90, and Na croscarmellose (10 mg of ARP in a 130 mg tablet)...
January 8, 2024: Pharmaceutical Development and Technology
https://read.qxmd.com/read/38133595/in-brief-three-new-injectable-antipsychotic-drugs
#2
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 25, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/38133585/drugs-for-depressionr
#3
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 11, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/38085556/safety-evaluation-in-iterative-development-of-wearable-patches-for-aripiprazole-tablets-with-sensor-pooled-analysis-of-clinical-trials
#4
JOURNAL ARTICLE
Michael Jan, Antonia Coppin-Renz, Robin West, Christophe Le Gallo, Jeffrey M Cochran, Emiel van Heumen, Michael Fahmy, J Corey Reuteman-Fowler
BACKGROUND: Wearable sensors in digital health may pose a risk for skin irritation through the use of wearable patches. Little is known about how patient- and product-related factors impact the risk of skin irritation. Aripiprazole tablets with sensor (AS, Abilify MyCite; Otsuka America Pharmaceutical, Inc) is a digital medicine system indicated for the treatment of patients with schizophrenia, bipolar I disorder, and major depressive disorder. AS includes aripiprazole tablets with an embedded ingestible event marker, a wearable sensor attached to the skin through a wearable patch, a smartphone app, and a web-based portal...
December 12, 2023: JMIR Formative Research
https://read.qxmd.com/read/37339089/brexpiprazole-rexulti-for-agitation-in-alzheimer-s-dementia
#5
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
June 26, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/37252199/cost-effectiveness-of-aripiprazole-tablets-with-sensor-versus-oral-atypical-antipsychotics-for-the-treatment-of-schizophrenia-using-a-patient-level-microsimulation-modeling-approach
#6
JOURNAL ARTICLE
Avijeet S Chopra, Dusica Hadzi Boskovic, Amit Kulkarni, Jeffrey M Cochran
OBJECTIVE: Strategies designed to track drug ingestion may improve medication adherence and clinical outcomes in adults with schizophrenia. This study aimed to estimate the cost-effectiveness of aripiprazole tablets with sensor (AS; Abilify MyCite® ) versus generic oral atypical antipsychotics (AAPs) in schizophrenia from the United States payer and societal perspectives over 12 months. METHODS: An individual-level microsimulation was developed to generate individual trajectories using data from a phase 3b multicenter, open-label, mirror-image trial in adults with schizophrenia treated prospectively for 6 months with AS...
2023: ClinicoEconomics and Outcomes Research: CEOR
https://read.qxmd.com/read/37216200/cariprazine-vraylar-for-adjunctive-treatment-of-depression
#7
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
May 29, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/36548028/digital-medicine-system-in-veterans-with-severe-mental-illness-feasibility-and-acceptability-study
#8
JOURNAL ARTICLE
Sarah Gonzales, Olaoluwa O Okusaga, J Corey Reuteman-Fowler, Megan M Oakes, Jamie N Brown, Scott Moore, Allison A Lewinski, Cristin Rodriguez, Norma Moncayo, Valerie A Smith, Shauna Malone, Justine List, Raymond Y Cho, Amy S Jeffreys, Hayden B Bosworth
BACKGROUND: Suboptimal medication adherence is a significant problem for patients with serious mental illness. Measuring medication adherence through subjective and objective measures can be challenging, time-consuming, and inaccurate. OBJECTIVE: The primary purpose of this feasibility and acceptability study was to evaluate the impact of a digital medicine system (DMS) among Veterans (patients) with serious mental illness as compared with treatment as usual (TAU) on medication adherence...
December 22, 2022: JMIR Formative Research
https://read.qxmd.com/read/36482352/treatment-with-aripiprazole-once-monthly-injectable-formulation-is-effective-in-improving-symptoms-and-global-functioning-in-schizophrenia-with-and-without-comorbid-substance-use-a-post-hoc-analysis-of-the-reliam-study
#9
JOURNAL ARTICLE
Howard C Margolese, Matthieu Boucher, Francois Therrien, Guerline Clerzius
BACKGROUND: ReLiAM, Real-Life Assessment of Abilify Maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (AOM) under real-life conditions. ReLiAM's primary aim was to evaluate the evolution of global functional status in patients treated with AOM for 12 months in Canada. METHODS: The objective of this post hoc analysis of the ReLiAM study is to investigate the treatment effects of real-life use of AOM over a 1-year period in the subgroup of patients with reported substance use compared with patients without substance use...
December 8, 2022: BMC Psychiatry
https://read.qxmd.com/read/36278274/-in-vitro-cytogenotoxic-evaluation-of-aripiprazole-on-human-peripheral-lymphocytes-and-computational-molecular-docking-analysis
#10
JOURNAL ARTICLE
Yasemin Eldemir Okay, İbrahim Halil Kenger, Hamit Yildiz, Mehmet Tahir Hüsunet, Lale Dönbak, Ahmet Kayraldiz
Two different drug groups, typical (classic) and atypical (new), are used in the treatment of schizophrenia. Aripiprazole, an atypical antipsychotic chemical, is the active ingredient of the drug Abilify. This study was conducted to determine the possible genotoxic effect of aripiprazole. For this purpose, four different doses of aripiprazole (5; 10; 20, and 40 µg/mL) were examined with Chromosome Abnormality (CA), Sister Chromatid Exchange (SCE), Micronucleus (MN) tests. Based on these tests, Proliferation Index (PI), Percent Abnormal Cells (AC), Mitotic Index (MI), Micronuclear Binuclear Cell (MNBN), and Nuclear Division Index (NDI) levels were determined in human peripheral lymphocytes treated for 24 and 48 hours...
October 24, 2022: Drug and Chemical Toxicology
https://read.qxmd.com/read/35923658/participant-engagement-and-symptom-improvement-aripiprazole-tablets-with-sensor-for-the-treatment-of-schizophrenia
#11
JOURNAL ARTICLE
Jeffrey M Cochran, Hui Fang, Christophe Le Gallo, Timothy Peters-Strickland, Jean-Pierre Lindenmayer, J Corey Reuteman-Fowler
Purpose: A recent, phase 3b, mirror-image clinical trial of outpatients with schizophrenia found that use of aripiprazole tablets with sensor (AS; Abilify MyCite® , comprising an ingestible event-marker sensor embedded in aripiprazole tablets, wearable sensor patches, and a smartphone application) reduced the incidence of psychiatric hospitalizations relative to oral standard-of-care antipsychotics. This analysis explored the relationship between AS engagement by participants and changes in participant performance and symptom-severity measures assessed by clinical raters...
2022: Patient Preference and Adherence
https://read.qxmd.com/read/35730516/letter-to-the-editor-rethinking-the-cost-of-antipsychotic-treatment-the-average-cost-of-the-drugs-used-in-turkey-in-2020
#12
JOURNAL ARTICLE
Mustafa Yıldız, Emre Osman
Dear Editor, The costs of antipsychotic drugs (APDs) used in the treatment of mental disorders with psychosis are mentioned in treatment guidelines (APA 2021, NICE 2014). While the American Psychiatric Association guideline states that every specialist should make decisions according to the rules and conditions of their country and their region, the National Institute of Health and Clinical Excellence guideline emphasizes that drug costs must be taken into consideration in the treatment process. Classical or first-generation antipsychotic drugs (FAPDs) are relatively cheaper in terms of sales prices compared to atypical or second-generation antipsychotic drugs (SAPDs) with a slightly different effect mechanism...
2022: Türk Psikiyatri Dergisi, Turkish Journal of Psychiatry
https://read.qxmd.com/read/35460508/impact-of-3-monthly-long-acting-injectable-paliperidone-palmitate-in-schizophrenia-a-retrospective-real-world-analysis-of-population-based-health-records-in-spain
#13
JOURNAL ARTICLE
Luis Gutiérrez-Rojas, Sergio Sánchez-Alonso, Marta García Dorado, Paola M López Rengel
BACKGROUND: Treatment of schizophrenia requires long-term medication to prevent relapse. Treatment nonadherence may increase the risk of relapse, leading to increased hospitalizations and emergency room (ER) visits. Long-acting injectables (LAIs) such as paliperidone palmitate have improved treatment adherence and therefore symptoms. However, real-world studies comparing 3-monthly LAI formulations with other LAIs and oral antipsychotics (OAs) are scarce. OBJECTIVE: The objective of this study was to investigate and evaluate the clinical effectiveness of paliperidone palmitate LAI monthly (PP1M; Xeplion® ) and 3-monthly (PP3M; Trevicta® ) formulations compared with the monthly LAI aripiprazole (AM; Abilify Maintena® ) and OAs in Spain...
April 23, 2022: CNS Drugs
https://read.qxmd.com/read/34979059/population-pharmacokinetic-modeling-and-exposure-response-analysis-for-aripiprazole-once-monthly-in-subjects-with-schizophrenia
#14
JOURNAL ARTICLE
Xiaofeng Wang, Arash Raoufinia, Sébastien Bihorel, Julie Passarell, Suresh Mallikaarjun, Luann Phillips
An intramuscular formulation of aripiprazole monohydrate dosed once monthly (AOM) was developed to address nonadherence with the approved oral tablets. A 3-compartment linear population pharmacokinetic model for oral and AOM doses was developed; relative bioavailability was estimated for AOM relative to oral dosing and body mass index and sex were significant predictors of AOM absorption rate constant (longer absorption half-life for women and absorption half-life increases with increasing body mass index)...
January 3, 2022: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/34793936/impact-of-jet-pulverization-and-wet-milling-techniques-on-properties-of-aripiprazole-long-acting-injection-and-absorption-mechanism-research-in-vivo
#15
JOURNAL ARTICLE
Xueting Guo, Maolian Zhang, Yibin Guo, Hao Liu, Bing Yang, Jingxin Gou, Tian Yin, Yu Zhang, Haibing He, Dongchun Liu, Xing Tang
This study aims to explore the influence of wet milling and jet pulverization on the aripiprazole microcrystalline long-acting injection. Crystal form and particle size distribution were taken as inspection indicators in vitro, and process parameters were optimized. The formulation prepared by wet milling (AMLAI-WM) was shown to undergo a slight conversion of crystal form by DSC, PXRD, TG, FT-IR and have a wider particle size distribution with D50 and Span values of 2.967 μm and 3.457 compared to the formulation fabricated by jet pulverization (AMLAI-JP) with 2...
November 15, 2021: International Journal of Pharmaceutics
https://read.qxmd.com/read/33960741/discovery-research-and-development-history-of-the-dopamine-d-2-receptor-partial-agonists-aripiprazole-and-brexpiprazole
#16
REVIEW
Tetsuro Kikuchi, Kenji Maeda, Mikio Suzuki, Tsuyoshi Hirose, Takashi Futamura, Robert D McQuade
Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify® ). The drug was approved for this indication in the United States in 2002 and has received approval in the United States, Europe, Japan, and many other countries for several indications including schizophrenia, acute mania, adjunctive treatment of major depressive disorder (MDD), irritability associated with autistic disorder, and Tourette's disorder...
June 2021: Neuropsychopharmacology Reports
https://read.qxmd.com/read/33710399/reproductive-safety-of-aripiprazole-data-from-the-massachusetts-general-hospital-national-pregnancy-registry-for-atypical-antipsychotics
#17
JOURNAL ARTICLE
Marlene P Freeman, Adele C Viguera, Lina Góez-Mogollón, Amanda V Young, Phoebe S Caplin, Sara A McElheny, Taylor R Church, David Chitayat, Sonia Hernández-Díaz, Lee S Cohen
Aripiprazole has become one of the most commonly prescribed psychotropics, making a more comprehensive understanding of its reproductive safety profile a priority. The goal of the current analysis was to determine the risk of major malformations in infants exposed during the first trimester of pregnancy to aripiprazole compared to infants whose mothers had psychiatric diagnoses but did not use an atypical antipsychotic during pregnancy. The National Pregnancy Registry for Atypical Antipsychotics is a prospective pharmacovigilance program in which pregnant women are enrolled and interviewed during pregnancy and the postpartum period...
August 2021: Archives of Women's Mental Health
https://read.qxmd.com/read/33347031/abilify-mycite-aripiprazole-a-critical-evaluation-of-the-novel-dosage-form
#18
JOURNAL ARTICLE
Ajay Kumar Shukla, Rekha Mehani, Balakrishnan Sadasivam
No abstract text is available yet for this article.
January 2021: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/33064050/a-safety-evaluation-of-aripiprazole-in-the-treatment-of-schizophrenia
#19
REVIEW
Adrian Preda, Bryan B Shapiro
INTRODUCTION: Aripiprazole is a third generation antipsychotic approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia. Aripiprazole is available as oral and long-acting injectable (LAI) depot formulations, with a unique mechanism of action comprising partial D2 and serotonin 5-HT1A agonism and antagonism at serotonin 5-HT2A receptors. AREAS COVERED: We review short-and-long-term clinical trials, meta-analyses of clinical trials and product information pertaining to the safety and efficacy of aripiprazole in adults with schizophrenia...
December 2020: Expert Opinion on Drug Safety
https://read.qxmd.com/read/31917736/when-to-raise-our-white-flag-a-discussion-of-scope-of-practice-in-a-resource-scarce-world
#20
JOURNAL ARTICLE
Elizabeth Barnhardt, Rebecca Baum, Mark Winerman, Pankhuree Vandana, Karen B Tabern, Marilyn Augustyn
Thomas is a 13-year-old boy with autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), generalized anxiety disorder, separation anxiety disorder, and major depressive disorder who presented for a follow-up to his developmental and behavioral pediatrician (DBP). His mother describes an increase in symptoms of anxiety and depression for the last 6 weeks, accompanied by suicidal ideation and thoughts of self-mutilation.Before this increase in symptoms, he had been doing well for the last several months with the exception of increasing weight gain, and Abilify was decreased from 5 mg to 2...
2020: Journal of Developmental and Behavioral Pediatrics: JDBP
keyword
keyword
40862
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.